Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy

Asia-Pacific Journal of Clinical Oncology

Volumn 9, Issue 1, 2013, Pages 71-79

  Min, Daliu ^a   Lin, Feng ^a   Shen, Zan ^a   Zheng, Shuier ^a   Tan, Lina ^a   Yu, Wenxi ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Chemotherapy; Multidisciplinary therapy; Osteosarcoma; Prognosis; Survival

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMPUTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CHINESE; DISEASE SEVERITY; FEMALE; HUMAN; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LEUCOVORIN; LIMB SALVAGE; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84874106283     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01560.x     Document Type: Article

References (35)

1. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
2. Marina N, Gebhardt M, Teot L etal. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422-441.
3. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001; 19: 292-315.
4. Bramwell VH. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol 1997; 24: 561-571.
5. Kager L, Zoubek A, Potschger U etal. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018.
6. Meyers PA, Heller G, Healey JH etal. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11: 449-453.
7. Meyers PA, Heller G, Healey JH etal. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
8. Rosen G, Marcove RC, Caparros B etal. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-2177.
9. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972; 30: 1627-1631.
10. Rosen G, Caparros B, Huvos AG etal. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-1230.
11. Ferrari S, Smeland S, Mercuri M etal. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-8852.
12. Kempf-Bielack B, Bielack SS, Jurgens H etal. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-568.
13. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153: 106-120.
14. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en block resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14-18.
15. Bielack SS, Kempf-Bielack B, Delling G etal. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
16. Saeter G, Elomaa I, Wahlqvist Y etal. Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 1997; 273: 156-160.
17. Bacci G, Briccoli A, Mercuri M etal. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998; 10: 69-76.
18. Bacci G, Briccoli A, Rocca M etal. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003; 14: 1126-1134.
19. Harris MB, Gieser P, Goorin AM etal. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 1998; 16: 3641-3648.
20. Tsuchiya H, Kanazawa Y, Mohamed E etal. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 2002; 20: 3470-3477.
21. Bacci G, Longhi A, Fagioli F etal. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27year experience at Rizzoli Institute, Italy. Eur J Cancer 2005; 41: 2836-2845.
22. Bacci G, Ferrari S, Delepine N etal. Predictive factors of histological response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998; 16: 658-663.
23. Jurgens H, Kosloff C, Niremberg A etal. Prognostic factors in the response of primary osteogenic sarcoma to the preoperative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monogr 1981; 56: 221-226.
24. Saeter G, Alvegrad TA, Elomaa I etal. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766-1775.
25. Bacci G, Briccoli A, Ferrari S etal. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000; 7: 339-346.
26. Lewis IJ, Nooij MA, Whelan J etal. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
27. Bacci G, Longhi A, Versari M etal. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106: 1154-1161.
28. Picci P, Sangiorgi L, Rougraff BT etal. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12: 2699-2705.
29. Man TK, Chintagumpala M, Visvanathan J etal. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 2005; 65: 8142-8150.
30. Anderson P. Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo Clin Proc 2003; 78: 145-146.
31. Bacci G, Briccoli A, Longhi A etal. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 2005; 44: 748-755.
32. Chou AJ, Merola PR, Wexler LH etal. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005; 104: 2214-2221.
33. Ferrari S, Briccoli A, Mercuri M etal. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715.
34. Bacci G, Picci P, Orlandi M etal. Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori 1987; 73: 331-336.
35. Bramer JA, Abudu AA, Tillman RM etal. Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma. Eur J Cancer 2005; 41: 2846-2852.